Research programme: MBL inhibitors - UniQuest

Drug Profile

Research programme: MBL inhibitors - UniQuest

Latest Information Update: 03 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Queensland
  • Developer UniQuest; University of Queensland
  • Class
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Bacterial infections

Most Recent Events

  • 03 Aug 2016 Research programme: MBL inhibitors - UniQuest is available for licensing -
  • 03 Aug 2016 Early research in Bacterial infections (Adjuvant therapy) in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top